X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse SHASUN PHARMA with ADCOCK INGRAM HOLDINGS LTD. - S. Africa - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SHASUN PHARMA vs ADCOCK INGRAM (S. Africa) - Comparison Results

ADCOCK INGRAM (S. Africa)
   Change

Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 SHASUN PHARMA   ADCOCK INGRAM
EQUITY SHARE DATA
    SHASUN PHARMA
Mar-14
ADCOCK INGRAM
Jun-14
SHASUN PHARMA/
ADCOCK INGRAM
5-Yr Chart
Click to enlarge
High Rs94403-   
Low Rs46291-   
Sales per share (Unadj.) Rs214.2119.9-  
Earnings per share (Unadj.) Rs5.3-30.2-  
Cash flow per share (Unadj.) Rs15.8-25.0-  
Dividends per share (Unadj.) Rs1.000-  
Dividend yield (eoy) %1.40-  
Book value per share (Unadj.) Rs53.394.1-  
Shares outstanding (eoy) m56.62168.78-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.32.9 11.3%   
Avg P/E ratio x13.1-11.5 -114.1%  
P/CF ratio (eoy) x4.4-13.9 -31.9%  
Price / Book Value ratio x1.33.7 35.5%  
Dividend payout %18.70-   
Avg Mkt Cap Rs m3,95858,557 6.8%   
No. of employees `000NA4.3 0.0%   
Total wages/salary Rs m2,1643,675 58.9%   
Avg. sales/employee Rs ThNM4,714.3-  
Avg. wages/employee Rs ThNM856.1-  
Avg. net profit/employee Rs ThNM-1,187.9-  
INCOME DATA
Net Sales Rs m12,12720,238 59.9%  
Other income Rs m229142 161.8%   
Total revenues Rs m12,35620,380 60.6%   
Gross profit Rs m1,009-3,507 -28.8%  
Depreciation Rs m594873 68.0%   
Interest Rs m415548 75.7%   
Profit before tax Rs m230-4,787 -4.8%   
Minority Interest Rs m0-13 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-73299 -24.3%   
Profit after tax Rs m302-5,100 -5.9%  
Gross profit margin %8.3-17.3 -48.0%  
Effective tax rate %-31.7-6.2 506.7%   
Net profit margin %2.5-25.2 -9.9%  
BALANCE SHEET DATA
Current assets Rs m6,88414,823 46.4%   
Current liabilities Rs m8,4568,340 101.4%   
Net working cap to sales %-13.032.0 -40.5%  
Current ratio x0.81.8 45.8%  
Inventory Days Days62111 55.6%  
Debtors Days Days108124 86.8%  
Net fixed assets Rs m4,9708,640 57.5%   
Share capital Rs m11394 120.6%   
"Free" reserves Rs m2,8750-   
Net worth Rs m3,02015,885 19.0%   
Long term debt Rs m1,8175,582 32.6%   
Total assets Rs m13,34730,008 44.5%  
Interest coverage x1.6-7.7 -20.1%   
Debt to equity ratio x0.60.4 171.2%  
Sales to assets ratio x0.90.7 134.7%   
Return on assets %5.4-15.2 -35.4%  
Return on equity %10.0-32.1 -31.2%  
Return on capital %13.3-19.8 -67.3%  
Exports to sales %46.40-   
Imports to sales %14.20-   
Net fx Rs m3,6690-   
CASH FLOW
From Operations Rs m3981,727 23.0%  
From Investments Rs m-1,635-530 308.2%  
From Financial Activity Rs m1,3095,066 25.8%  
Net Cashflow Rs m716,263 1.1%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ADCOCK INGRAM (S. Africa) is South Africa Rand. All data has been converted at 5.56 Rs / ZAR

Compare SHASUN PHARMA With: ACTAVIS (US)  MYLAN (US)  TEVA PHARMA (Israel)  

Compare SHASUN PHARMA With: LUPIN LTD  FULFORD INDIA  CIPLA  J.B.CHEMICALS  PFIZER  



Today's Market

Indian Indices Trade Strong; Metal, Pharma Stocks Lead Gains(01:30 pm)

After opening the day in green, share markets in India have continued the momentum and are presently trading above the dotted line.

Related Views On News

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SHASUN PHARMA SHARE PRICE


Nov 17, 2015 (Close)

TRACK SHASUN PHARMA

  • Track your investment in SHASUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SHASUN PHARMA 5-YR ANALYSIS

COMPARE SHASUN PHARMA WITH

MARKET STATS